This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Merrill, Joan
Item Type | Name |
Concept
|
Drug Administration Schedule
|
Academic Article
|
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
|
Academic Article
|
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
|
Academic Article
|
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
|
Academic Article
|
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE).
|
Academic Article
|
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
|
Academic Article
|
Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
|
- Drug Administration Schedule